Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics. The French pharma company ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

Great hopes rest on a product from the French-Austrian company Valneva. However, a vaccine from U.S. company Novavax, also based on proven technology, may reach more markets this winter.

The company has a market cap of $548.51 million, a PE ratio of -51.92 and a beta of 1.98. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a current ratio of 2.78 ...

Valneva Trading Down 5.9 % Valneva stock opened at $7.44 on Friday. The stock has a market cap of $604.57 million, a PE ratio of -57.23 and a beta of 1.98. Valneva has a 52 week low of $3.62 and a ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 - ...